These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12798697)

  • 1. Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis.
    Hu J; Khanna V; Jones MW; Surti U
    Gynecol Oncol; 2003 Jun; 89(3):369-75. PubMed ID: 12798697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization.
    Hauptmann S; Denkert C; Koch I; Petersen S; Schlüns K; Reles A; Dietel M; Petersen I
    Hum Pathol; 2002 Jun; 33(6):632-41. PubMed ID: 12152163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.
    Staebler A; Heselmeyer-Haddad K; Bell K; Riopel M; Perlman E; Ried T; Kurman RJ
    Hum Pathol; 2002 Jan; 33(1):47-59. PubMed ID: 11823973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma.
    Staebler A; Karberg B; Behm J; Kuhlmann P; Neubert U; Schmidt H; Korsching E; Bürger H; Lelle R; Kiesel L; Böcker W; Shih IeM; Buchweitz O
    Genes Chromosomes Cancer; 2006 Oct; 45(10):905-17. PubMed ID: 16845658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas.
    Tapper J; Bützow R; Wahlström T; Seppälä M; Knuutila S
    Br J Cancer; 1997; 75(12):1782-7. PubMed ID: 9192982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease.
    Skirnisdottir I; Mayrhofer M; Rydåker M; Akerud H; Isaksson A
    BMC Cancer; 2012 Sep; 12():407. PubMed ID: 22967087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic imbalances in ovarian borderline serous and mucinous tumors.
    Hu J; Khanna V; Jones MM; Surti U
    Cancer Genet Cytogenet; 2002 Nov; 139(1):18-23. PubMed ID: 12547152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation.
    Kiechle M; Jacobsen A; Schwarz-Boeger U; Hedderich J; Pfisterer J; Arnold N
    Cancer; 2001 Feb; 91(3):534-40. PubMed ID: 11169935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification.
    Nowee ME; Snijders AM; Rockx DA; de Wit RM; Kosma VM; Hämäläinen K; Schouten JP; Verheijen RH; van Diest PJ; Albertson DG; Dorsman JC
    J Pathol; 2007 Sep; 213(1):46-55. PubMed ID: 17668415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas.
    Sonoda G; Palazzo J; du Manoir S; Godwin AK; Feder M; Yakushiji M; Testa JR
    Genes Chromosomes Cancer; 1997 Dec; 20(4):320-8. PubMed ID: 9408747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian carcinomas in endometriosis: an immunohistochemical and comparative genomic hybridization study.
    Mhawech P; Kinkel K; Vlastos G; Pelte MF
    Int J Gynecol Pathol; 2002 Oct; 21(4):401-6. PubMed ID: 12352189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplicon profiles in ovarian serous carcinomas.
    Nakayama K; Nakayama N; Jinawath N; Salani R; Kurman RJ; Shih IeM; Wang TL
    Int J Cancer; 2007 Jun; 120(12):2613-7. PubMed ID: 17351921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays.
    Mayr D; Kanitz V; Anderegg B; Luthardt B; Engel J; Löhrs U; Amann G; Diebold J
    Am J Clin Pathol; 2006 Jul; 126(1):101-9. PubMed ID: 16753589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
    Engler DA; Gupta S; Growdon WB; Drapkin RI; Nitta M; Sergent PA; Allred SF; Gross J; Deavers MT; Kuo WL; Karlan BY; Rueda BR; Orsulic S; Gershenson DM; Birrer MJ; Gray JW; Mohapatra G
    PLoS One; 2012; 7(2):e30996. PubMed ID: 22355333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease.
    Kim SW; Kim JW; Kim YT; Kim JH; Kim S; Yoon BS; Nam EJ; Kim HY
    Genes Chromosomes Cancer; 2007 Jan; 46(1):1-9. PubMed ID: 17044060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
    Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
    Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage.
    Partheen K; Levan K; Osterberg L; Helou K; Horvath G
    Genes Chromosomes Cancer; 2004 Aug; 40(4):342-8. PubMed ID: 15188458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the genetic changes detected in the primary and secondary tumor sites of ovarian cancer using comparative genomic hybridization.
    Fishman A; Shalom-Paz E; Fejgin M; Gaber E; Altaras M; Amiel A
    Int J Gynecol Cancer; 2005; 15(2):261-6. PubMed ID: 15823109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.